The Food and Drug Administration recently approved a new flu immunization developed by Cambridge, Mass.-based Seqirus.
Afluria Quadrivalent is an inactivated influenza vaccine intended to protect patients against four different flu viruses — two Type A viruses and two Type B viruses. The vaccine comes in a single-dose pre-filled syringe.
In May, Seqirus received FDA approval for another quadrivalent flu vaccine called Flucelvax.
Afluria Quadrivalent will be available in the U.S. for this year's flu season.
More articles on supply chain:
FDA fast tracks experimental drug to treat Parkinson's
The rise of the unbranded drug ad: 5 things to know
Mylan to introduce generic EpiPen at half the price